Avanir Pharmaceuticals Inc., an Aliso Viejo drug maker, said Thursday that regulators gave marketing approval for a new formulation of its FazaClo schizophrenia drug.
Avanir’s shares closed up about 7% Thursday with a market value of about $150 million.
The Food and Drug Administration cleared the marketing of FazaClo’s new formulation, which comes with bottle packaging and a new, lower 12.5 milligram dosage.
Avanir saw a set back in October when regulators asked for more data on Zenvia, a drug candidate, instead of approving it.
